Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Other Non-Current Assets data on file, last reported at $11.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 12.24% year-over-year to $11.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (up 12.24% YoY), and the FY2025 full-year result was $13.7 million, up 12.16% from the prior year.
• Other Non-Current Assets fell to $11.6 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $16.1 million in Q3 2023 to a low of $2.4 million in Q1 2022.
• A 5-year average of $11.2 million and a median of $12.1 million in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets slumped 51.32% in 2022 and surged 279.13% in 2023, its largest moves.
• Tracing ANIP's Other Non-Current Assets over 5 years: stood at $11.4 million in 2022, then gained by 6.26% to $12.1 million in 2023, then advanced by 1.23% to $12.2 million in 2024, then gained by 12.16% to $13.7 million in 2025, then declined by 15.55% to $11.6 million in 2026.
• Business Quant data shows ANIP's Other Non-Current Assets at $11.6 million in Q1 2026, $13.7 million in Q4 2025, and $12.5 million in Q3 2025.